Bisphosphonates are the cornerstone for the management of multiple myeloma bone disease. Several international organisations recommend the use of bisphosphonates in patients with newly diagnosed myeloma and bone disease (presence of lytic lesions as shown with conventional radiography or diffuse osteoporosis due to myeloma) for 2 years and for those who relapse. In the USA, intravenous zoledronic acid and pamidronic acid are used in the treatment of multiple myeloma, whereas in some European countries...